Picking the Perfect Atopic Dermatitis Therapy with Matthew Zirwas, MD
Dermatology Times
SEPTEMBER 18, 2024
From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Dermatology Times
SEPTEMBER 18, 2024
From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.
Dermatology Times
OCTOBER 3, 2023
These insights highlight the crucial role of systemic therapies in the comprehensive management of moderate to severe atopic dermatitis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dermatology Times
OCTOBER 27, 2024
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
First Derm
JUNE 10, 2024
Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.
Dermatology Times
AUGUST 27, 2024
The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.
Dermatology Times
OCTOBER 5, 2023
Colleen Cotton, MD, discusses the treatment landscape of pediatric atopic dermatitis, highlights from her session at Maui Derm NP+PA in Asheville, NC, and more.
Dermatology Times
OCTOBER 28, 2024
Posters at AMCP Nexus analyzed the burden of flares on patients with atopic dermatitis (AD) and the impact initiating ruxolitinib cream had on use of other therapies.
Dermatology Times
JUNE 2, 2024
James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.
First Derm
FEBRUARY 21, 2024
Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?
Dermatology Times
AUGUST 9, 2024
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
Dermatology Times
MARCH 29, 2024
Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.
US Dermatologt Partners
NOVEMBER 25, 2023
Atopic dermatitis (AD) is a multifaceted condition that can significantly impact a patient’s quality of life. I think that dermatitis started showing up once my psoriasis started showing up,” Dean said. “It As a physician, I have to do a better job intervening here [and] switch our systemic therapies.”
Dermatology Times
MARCH 4, 2024
Test your knowledge on the AAD's recommendations for phototherapy, monoclonal antibodies, JAK inhibitors, and systemic therapies in the latest guidelines.
Dermatology Times
JUNE 20, 2024
Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation (..)
Dermatology Times
APRIL 11, 2024
In one study, researchers were unable to detect any changes in the gut microbiome of patients treated with tapering dose of steroids or a probiotic mixture.
The Dermatology Digest
JANUARY 29, 2024
From new topical therapies and novel biologics including nemolizumab and lebrikizumab to OX40 and OX40 ligand monoclonal antibodies, the atopic dermatitis pipeline is full, says Andrew Blauvelt, MD, MBA, an Investigator at Oregon Medical Research Center in Portland. appeared first on The Dermatology Digest.
Dermatology Times
SEPTEMBER 20, 2023
Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance. The study appears in Dermatitis.
Dermatology Times
JULY 13, 2024
A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.
Dermatology Times
JUNE 2, 2024
James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.
US Dermatologt Partners
AUGUST 23, 2023
Atopic Dermatitis, more commonly known as eczema, is a common skin condition impacting one in 10 Americans. In this blog, Dr. Ackerman walks through just what atopic dermatitis is, how dermatologists help, available medications an treatments, and at-home care steps. Millions of people in the U.S.
Dermatology Times
DECEMBER 7, 2023
A patient returns to your clinic seeking systemic therapy for her AD while postpartum and breastfeeding. Test your knowledge on injectables.
Dermatology Times
FEBRUARY 17, 2024
Investigators revealed the development of a non-invasive molecular test utilizing gene expression differences in skin diseases such as atopic dermatitis, psoriasis, and mycosis fungoides, with the potential to accurately diagnose and identify super-responders to targeted systemic therapies.
Dermatology Times
OCTOBER 3, 2023
As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.
Dermatology Times
DECEMBER 11, 2023
From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.
Dermatology Times
DECEMBER 12, 2023
At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."
Dermatology Times
MAY 30, 2024
Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)
Dermatology Times
AUGUST 12, 2024
Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.
Dermatology Times
JULY 1, 2024
James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.
Dermatology Times
NOVEMBER 3, 2023
Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.
The Dermatology Digest
OCTOBER 26, 2024
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.
Dermatology Times
JANUARY 8, 2024
The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.
Dermatology Times
AUGUST 12, 2024
This week’s collection of the latest dermatologic studies includes the impact of isotretinoin treatment on femoral cartilage thickness, cystic fibrosis dermatitis arthritis syndrome, the role of intratumoral therapies for cutaneous melanoma, and fractional pigment toning for treating benign epidermal pigmented lesions.
Dermatology Times
JULY 24, 2024
A recent study saw a “significant” decrease in allergen-specific IgE levels over a 1-year period of dupilumab therapy in children with atopic dermatitis.
First Derm
MARCH 22, 2024
Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Who’s at Risk : Affects both genders and all ages, but more common in infants and children with atopic dermatitis.
Dermatology Times
DECEMBER 22, 2023
The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.
The Dermatology Digest
MARCH 7, 2024
Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Just because they are little doesn’t mean we should be afraid to treat them and make their skin disease better,” she stresses. Watch Now SOCS Turns 20!
The Dermatology Digest
MARCH 7, 2024
More Conference Coverage Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now SOCS Turns 20!
First Derm
JUNE 23, 2024
1] Three main categories of eczema are atopic eczema, contact dermatitis and stasis dermatitis. To prevent that your dermatologist will advice you to slowly taper off the topical steroid, shift from high to mild potency ones, or every other day therapy. The American Contact Dermatitis Society recognizes it as an allergen.
The Dermatology Digest
JUNE 12, 2024
A human, monoclonal antibody targeting the interleukin (IL)-13 cytokine, tralokinumab is currently indicated in patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
The Dermatology Digest
FEBRUARY 26, 2024
2 In this review, we highlight the “epithelial barrier hypothesis” proposed by Akdis, discuss the important roles of the skin, gut, and respiratory barriers, and discuss novel therapies. Impairment in tight junction expression has been shown to contribute to the barrier dysfunction observed in patients with atopic dermatitis.
The Dermatology Digest
MARCH 7, 2024
Emma Guttman-Yassky, MD, PhD, the Waldman Professor of Dermatology and Immunology and Health System Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City, discusses the factors that can affect choice of systemic therapy for atopic dermatitis (AD) patients. Watch Now SOCS Turns 20!
The Dermatology Digest
JUNE 14, 2024
The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois, showed that upadacitinib bested dupilumab for all ranked secondary endpoints of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.
The Dermatology Digest
MARCH 7, 2024
More Conference Coverage Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now SOCS Turns 20!
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content